CagriSema (Cagrilintide 2.5 mg + Semaglutide 2.5 mg)

CagriSema is a combination research system incorporating Cagrilintide and Semaglutide. This formulation contains Cagrilintide 2.5 mg + Semaglutide 2.5 mg.

Cagrilintide is a long-acting amylin analogue investigated in research involving amylin receptor-related signaling, appetite and satiety regulation, food intake, and energy-balance mechanisms.

Semaglutide is a GLP-1 receptor agonist studied in connection with GLP-1 receptor signaling, glucose homeostasis, insulin and glucagon regulation, gastric emptying, and energy intake.

As a combined research formulation, CagriSema provides a system for investigating interactions between amylin and GLP-1 signaling pathways and their relationships with appetite regulation, energy homeostasis, glucose metabolism, and body-weight-related metabolic mechanisms.

The safety, efficacy, or appropriate human dosing of this specific 2.5 mg + 2.5 mg formulation should not be inferred from research or approved uses involving the individual components.

El envío se cobra según el número de artículos del pedido, con las mismas tarifas para todos los destinos, y el importe exacto aparece al finalizar la compra antes de pagar. Los pedidos salen en 1 día laborable.

¿No te convence? Devuélvelo en 30 días y te reembolsamos el importe completo, aunque esté abierto.